Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$9.98 USD
+0.06 (0.60%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $9.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Syndax Pharmaceuticals, Inc.'s return on equity, or ROE, is -101.60% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that SNDX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SNDX 9.98 +0.06(0.60%)
Will SNDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
Other News for SNDX
Earnings Scheduled For August 4, 2025
Syndax Pharmaceuticals (SNDX) Anticipates Q2 Earnings Announcement
Syndax Pharmaceuticals Q2 2025 Earnings Preview
Syndax Pharmaceuticals's Earnings: A Preview
Franklin Biotechnology Discovery Fund Q2 2025 Commentary